VNRX VolitionRX Limited Forecast, Technical & Fundamental Analysis
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis... Show more
VNRX is expected to report earnings to fall 35.88% to -62 cents per share on August 19
Q2'26
Est.
$-0.62
Q1'26
Missed
by $0.93
Q4'25
Missed
by $0.95
Q3'25
Missed
by $0.01
Q2'25
Missed
by $0.01
The last earnings report on May 15 showed earnings per share of -97 cents, missing the estimate of -3 cents. With 104.69K shares outstanding, the current market capitalization sits at 15.97M.
A.I.dvisor tells us that VNRX and STRRP have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that VNRX and STRRP's prices will move in lockstep.
The RSI Indicator for VNRX moved into overbought territory on June 22, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where VNRX advanced for three days, in of 218 cases, the price rose further within the following month. The odds of a continued upward trend are .
VNRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on June 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VNRX as a result. In of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for VNRX turned negative on June 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at .
VNRX moved below its 50-day moving average on May 26, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VNRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for VNRX entered a downward trend on May 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (10.753). P/E Ratio (0.000) is within average values for comparable stocks, (61.509). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.702). VNRX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.018). P/S Ratio (3.182) is also within normal values, averaging (23.786).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. VNRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VNRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
